GMED Stock Chart & Stats
$1390.45
$0.00(0.00%)
At close: 4:00 PM EDT
$1390.45
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,000.00 - $1,916.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$176.88B
Enterprise Value$10.37K
Total Cash (Recent Filing)$595.14M
Total Debt (Recent Filing)$111.19M
Price to Earnings (P/E)18.8
Beta0.23
Next Earnings
Nov 10, 2026EPS Estimate
21.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding111,831,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,790.01Price Target Upside28.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)86.15
Revenue Forecast (FY)$55.12B
Bulls Say, Bears Say
Bulls Say
Broad-Based Revenue GrowthGrowth across U.S. Spine, International Spine, and Trauma indicates broadening demand rather than reliance on one product area. This diversification can support durable revenue expansion, improve commercial leverage, and strengthen Globus Medical’s position across musculoskeletal procedures.
Margin Expansion And Cash GenerationMeaningful EBITDA expansion alongside strong operating cash flow demonstrates improving operating leverage and financial flexibility. Robust internally generated funds can support product investment, integration work, capital allocation, and resilience while the company continues expanding its portfolio.
Product And Robotic AdoptionRising robotic utilization, growing system deployments, and continued product launches show sustained adoption of Globus Medical’s technology and innovation pipeline. A larger installed base can encourage recurring procedure pull-through and deepen relationships with surgeons and hospitals.
Bears Say
Enabling Technology Revenue PressureThe transition from upfront equipment sales to flexible acquisition models is structurally changing revenue timing and reducing near-term cash sales. Even with growing deployments, this mix shift can delay reported growth and complicate visibility until associated procedure pull-through develops.
Nevro Integration And Demand PressureNevro’s declining sales and ongoing integration changes create a continuing execution burden within the combined portfolio. Until trial volumes recover and commercial operations stabilize, the business may face slower consolidated growth and additional management attention devoted to integration.
Uneven Margin And Cash Conversion HistoryThe recovery in profitability is encouraging, but historical inconsistency and lower TTM gross margin indicate that earnings quality remains sensitive to mix, pricing, and cost conditions. Such volatility can limit confidence in the durability of current margins and cash conversion.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $1000.00 and its highest was $1916.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $176.88B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Nov 10, 2026 which is in 44 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Aug 06, 2026. The company reported $23.697 earnings per share for the quarter, beating the consensus estimate of $19.435 by $4.262.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 21.15.
How many shares outstanding does Globus Medical have?
Globus Medical has 111,831,820 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $23.697 in its last earnings report, beating expectations of $19.435. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in MX:GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,790.01 (28.74% Upside)
$1,790.01 (28.74% Upside)
Blogger Sentiment
Bullish
MX:GMED Sentiment 82%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $77.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.24%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
GMED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.View all MX:GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$1,790.01
▲(28.74% Upside)